Frequency of Occurrence and Antimicrobial Susceptibility of Bacteria Isolated from Patients Hospitalised with Bacterial Pneumonia in Western and Eastern Europe (SENTRY Program; 2021–2022)
Frequency of Occurrence and Antimicrobial Susceptibility of Bacteria Isolated from Patients Hospitalised with Bacterial Pneumonia in Western and Eastern Europe (SENTRY Program; 2021–2022). Lead Author: Helio S. Sader, presented at ECCMID, 27-30 April 2024, Barcelona, Spain
Poster #3220
Activity of gepotidacin against Klebsiella pneumoniae, including molecularly characterized fluoroquinolone not susceptible subsets causing urinary tract infections in Europe and adjacent regions (2019–2022).
Activity of gepotidacin against <i>Klebsiella pneumoniae<i>, including molecularly characterized fluoroquinolone not susceptible subsets causing urinary tract infections in Europe and adjacent regions (2019–2022). Lean Author: Rodrigo Mendes, presented at ECCMID, 27-30 April 2024, Barcelona, Spain
Poster #P1441
Activity of aztreonam-avibactam and comparator agents against a global collection of metallo-β-lactamase-producing Enterobacterales
Activity of aztreonam-avibactam and comparator agents against a global collection of metallo-β-lactamase-producing Enterobacterales. Lead Author: Mariana Castanheira, presented at ECCMID, 27-30 April 2024, Barcelona, Spain
Poster #1439
β-lactam resistance mechanisms in baseline Enterobacterales from the REVISIT and ASSEMBLE aztreonam-avibactam Phase 3 clinical trials
β-lactam resistance mechanisms in baseline Enterobacterales from the REVISIT and ASSEMBLE aztreonam-avibactam Phase 3 clinical trials. Lead Author: Rodrigo Mendes at ECCMID, 27-30 April 2024, Barcelona, Spain
Poster #P1824
High-level plazomicin exposure selects for mutations in fusA, ratA, and a novel two-component system in Morganella morganii
High-level plazomicin exposure selects for mutations in fusA, ratA, and a novel two-component system in <i>Morganella morganii</i>. Lead Author: John H. Kimbrough, presented at ECCMID, 27-30 April 2024, Barcelona, Spain
Poster #P1694
Activity of cefiderocol against carbapenem non-susceptible Enterobacterales, including molecularly characterized clinical isolates causing infection in hospitals in European and adjacent regions (2020–2022)
Activity of cefiderocol against carbapenem non-susceptible Enterobacterales, including molecularly characterized clinical isolates causing infection in hospitals in European and adjacent regions (2020–2022). Lead Author: Rodrigo Mendes, presented at ECCMID, 27-30 April 2024, Barcelona, Spain
Poster #P1406
Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents against a Large Collection of Stenotrophomonas maltophilia Isolates Collected in Europe, Asia, and Latin America (2018–2023)
Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents against a Large Collection of <i>Stenotrophomonas maltophilia</i> Isolates Collected in Europe, Asia, and Latin America (2018–2023). Lead Author: Helio S. Sader, presented at ECCMID, 27-30 April 2024, Barcelona, Spain
Poster #1357
In vitro Activity of Gepotidacin and Comparator Agents Against a Collection of Klebsiella pneumoniae Urine Isolates Collected from Europe during 2019–2022
In vitro Activity of Gepotidacin and Comparator Agents Against a Collection of <i>Klebsiella pneumoniae</i> Urine Isolates Collected from Europe during 2019–2022. Presenting Author: S. J. Ryan Arends, Ph.D., at ECCMID, 27-30 April 2024, Barcelona, Spain
Poster #2433
Use of Voriconazole to Predict Susceptibility and Resistance to Isavuconazole for Aspergillus fumigatus by Using the CLSI Methods and Interpretive Criteria
Use of Voriconazole to Predict Susceptibility and Resistance to Isavuconazole for <i>Aspergillus fumigatus</i> by Using the CLSI Methods and Interpretive Criteria. Lead Author: Mariana Castanheira, presented at ECCMID, 27-30 April 2024, Barcelona, Spain
Poster #2930
Analysis of Resistance to Oral Standard-of-Care Antibiotics for Urinary Tract Infections Caused By Escherichia coli and Staphylococcus saprophyticus Collected in Europe in 2022
Analysis of Resistance to Oral Standard-of-Care Antibiotics for Urinary Tract Infections Caused By <i>Escherichia coli</i> and <i>Staphylococcus saprophyticus</i> Collected in Europe in 2022. Presenting Author: S. J. Ryan Arends at ECCMID, 27-30 April 2024, Barcelona, Spain
Poster #MTV11-06
Activity of cefiderocol against carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex, including molecularly characterized clinical isolates, causing infections in hospitals in European and adjacent regions (2020–2022)
Activity of cefiderocol against carbapenem-resistant <i>Acinetobacter baumannii-calcoaceticus</i> complex, including molecularly characterized clinical isolates, causing infections in hospitals in European and adjacent regions (2020–2022). Lead Author: Rodrigo Mendes, presented at ECCMID, 27-30 April 2024, Barcelona, Spain
Poster #MTV0604
Rezafungin Activity Against Echinocandin–Nonwildtype Candida glabrata Clinical Isolates Collected in European countries (2014–2021)
Rezafungin Activity Against Echinocandin–Nonwildtype <i>Candida glabrata</i> Clinical Isolates Collected in European countries (2014–2021). Lead Author: Mariana Castanheira, presented at ECCMID, 27-30 April 2024, Barcelona, Spain
Activity of cefiderocol against carbapenem non-susceptible Pseudomonas aeruginosa, including molecularly characterized clinical isolates, causing infections in hospitals in European and adjacent regions (2020–2022)
Activity of cefiderocol against carbapenem non-susceptible <i>Pseudomonas aeruginosa</i>, including molecularly characterized clinical isolates, causing infections in hospitals in European and adjacent regions (2020–2022). Lead Author: Rodrigo Mendes, presented at ECCMID, 27-30 April 2024, Barcelona, Spain
Poster #MTV0605
Activity of gepotidacin against molecularly characterized Klebsiella pneumoniae isolates from patients with urinary tract infections in Europe and adjacent regions (2019–2022)
Activity of gepotidacin against molecularly characterized Klebsiella pneumoniae isolates from patients with urinary tract infections in Europe and adjacent regions (2019–2022). Lead Author: Rodrigo Mendes at ECCMID, 27-30 April 2024, Barcelona, Spain
Poster #P2479
Proposed zosurabalpin broth microdilution quality control ranges using Clinical and Laboratory Standards Institute M23 Tier 2 criteria
Proposed zosurabalpin broth microdilution quality control ranges using Clinical and Laboratory Standards Institute M23 Tier 2 criteria. Lead Author: Michael Huband, presented at ECCMID, 27-30 April 2024, Barcelona, Spain
Poster #P2452
Genetic relationship and mechanisms contributing to reduced gepotidacin susceptibility in isolates from EAGLE- 2/EAGLE-3 clinical trials for uncomplicated urinary tract infections
Genetic relationship and mechanisms contributing to reduced gepotidacin susceptibility in isolates from EAGLE-2/EAGLE-3 clinical trials for uncomplicated urinary tract infections. Presenting Author: Rodrigo Mendes at ECCMID, 27-30 April 2024, Barcelona, Spain
Poster #1052
Bloodstream Infections in European Hospitals: Aetiology and Antimicrobial Susceptibility Results from the SENTRY Antimicrobial Surveillance Program (2021–2022)
Bloodstream Infections in European Hospitals: Aetiology and Antimicrobial Susceptibility Results from the SENTRY Antimicrobial Surveillance Program (2021–2022). Lead Author: Helio S. Sader, presented at ECCMID, 27-30 April 2024, Barcelona, Spain
In Vitro Antimicrobial Activity of Taurolidine against Associated with Catheter-Related Bloodstream Infections
In Vitro Antimicrobial Activity of Taurolidine against Associated with Catheter-Related Bloodstream Infections. Lead authors: Jared L. Crandon, PharmD presented at SHEA Spring Conference 2024 Houston, TX
Poster #130
Trend Analysis of Oritavancin and Comparator Agents’ Activities against Enterococcus species Causing Infections in US Medical Centers between 2017–2019 and 2022
Trend Analysis of Oritavancin and Comparator Agents’ Activities against Enterococcus species Causing Infections in US Medical Centers between 2017–2019 and 2022. Lead author: Cecilia G. Carvalhaes, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.
Poster #734
Activity of Sulbactam-Durlobactam, Antibacterial Combinations, and Comparators Against a Challenge Set of 66 Acinetobacter baumannii-calcoaceticus Species Complex Isolates
Activity of Sulbactam-Durlobactam, Antibacterial Combinations, and Comparators Against a Challenge Set of 66 Acinetobacter baumannii-calcoaceticus Species Complex Isolates. Lead author: MD Huband, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.
Poster #2517
Antimicrobial Spectrum of Plazomicin and Other Aminoglycosides against Multidrug-Resistant and Carbapenem-Resistant Enterobacterales When Applying New Breakpoints
Antimicrobial Spectrum of Plazomicin and Other Aminoglycosides against Multidrug-Resistant and Carbapenem-Resistant Enterobacterales When Applying New Breakpoints. Lead author: Helio S. Sader, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.
Poster #2801
Characterization of Methicillin-resistant Staphylococcus aureus Bloodstream Isolates Recovered from Patients Enrolled in a Randomized, Double-blind, Multi-center Study to Establish the Efficacy and Safety of Ceftobiprole for Treatment of Bacteremia, Including Infective Endocarditis
Characterization of Methicillin-resistant Staphylococcus aureus Bloodstream Isolates Recovered from Patients Enrolled in a Randomized, Double-blind, Multi-center Study to Establish the Efficacy and Safety of Ceftobiprole for Treatment of Bacteremia, Including Infective Endocarditis. Lead author: Rodrigo E. Mendes, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.
Poster #2785
Activity of Aztreonam-avibactam and Ceftazidime-avibactam against United States Isolates Producing β-lactamases (2020–2021)
Activity of Aztreonam-avibactam and Ceftazidime-avibactam against United States Isolates Producing β-lactamases (2020–2021). Lead author: Mariana Castanheira, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.
Poster #2756
Delafloxacin and Comparator Fluoroquinolones In Vitro Resistance Trends in Isolates from Skin and Skin Structure Infections in the USA (2017–2022)
Delafloxacin and Comparator Fluoroquinolones In Vitro Resistance Trends in Isolates from Skin and Skin Structure Infections in the USA (2017–2022). Lead author: Michael D. Huband, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.
Poster #2754
Rezafungin Activity against Invasive Candidiasis Isolates Globally: Results from the 2022 Rezafungin Surveillance Program
Rezafungin Activity against Invasive Candidiasis Isolates Globally: Results from the 2022 Rezafungin Surveillance Program. Lead author: Cecilia G. Carvalhaes, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.
Poster #2115
High Rates of Non-Susceptibility to Common Oral Antibiotics Among Streptococcus pneumoniae Clinical Isolates from the United States (2019–2021)
High Rates of Non-Susceptibility to Common Oral Antibiotics Among Streptococcus pneumoniae Clinical Isolates from the United States (2019–2021). Lead author: Lalitagauri M. Deshpande, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.
Poster #2139
In Vitro Antimicrobial Activity of Taurolidine against Candida auris Bloodstream Isolates from Global Sources
In Vitro Antimicrobial Activity of Taurolidine against Candida auris Bloodstream Isolates from Global Sources. Lead author: Antony Pfaffle, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.
Poster #2117
Activity of Ceftobiprole Against Enterococcus faecalis Clinical Isolates From the United States (2016–2020), Including Those From Difficult-to-Treat Infections
Activity of Ceftobiprole Against Enterococcus faecalis Clinical Isolates From the United States (2016–2020), Including Those From Difficult-to-Treat Infections. Lead author: Rodrigo Mendes, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.
Poster #2173
Activity of Meropenem-Vaborbactam Tested against Burkholderia Species Isolates
Activity of Meropenem-Vaborbactam Tested against Burkholderia Species Isolates. Lead author: Mariana Castanheira, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.
Poster #2757
Activity of Aztreonam-avibactam and Carbapenem-resistant Enterobacterales Isolates Collected in a Six-year Period (2017–2022)
Activity of Aztreonam-avibactam and Carbapenem-resistant Enterobacterales Isolates Collected in a Six-year Period (2017–2022). Lead author: Mariana Castanheira, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.
Poster #2755
Evaluation of the VITEK®2 XL Antimicrobial Susceptibility Testing for Non-fermenter Gram-Negative Bacilli: The Importance of Continuing to Monitor Antimicrobial Susceptibility Testing (AST) Systems
Evaluation of the VITEK®2 XL Antimicrobial Susceptibility Testing for Non-fermenter Gram-Negative Bacilli: The Importance of Continuing to Monitor Antimicrobial Susceptibility Testing (AST) Systems. Lead author: Cecilia G. Carvalhaes, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.
Poster #568
Antimicrobial Activity of Aztreonamavibactam, Ceftazidime-avibactam, and Meropenem-vaborbactam against Enterobacterales causing Bloodstream Infection in US Medical Centers (2020–2022)
Antimicrobial Activity of Aztreonamavibactam, Ceftazidime-avibactam, and Meropenem-vaborbactam against Enterobacterales causing Bloodstream Infection in US Medical Centers (2020–2022). Lead author: Helio S. Sader, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.
Poster #2146
In Vitro Antimicrobial Activity of Ceftobiprole against Streptococcus pneumoniae Isolates from the United States (2016–2020)
In Vitro Antimicrobial Activity of Ceftobiprole against Streptococcus pneumoniae Isolates from the United States (2016–2020). Lead author: Leonard Duncan, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.
Poster #2162
Evaluation of Isavuconazole Activity Against Non-fumigatus Aspergillus and Cryptic Aspergillus Species Causing Invasive Infections Worldwide
Evaluation of Isavuconazole Activity Against Non-fumigatus Aspergillus and Cryptic Aspergillus Species Causing Invasive Infections Worldwide. Lead author: Cecilia G. Carvalhaes, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.
Poster #P2114
Analysis of Resistance to Oral Standard-of-Care Antibiotics for Urinary Tract Infections Caused By Escherichia coli and Staphylococcus saprophyticus Collected in the United States in 2022
Analysis of Resistance to Oral Standard-of-Care Antibiotics for Urinary Tract Infections Caused By Escherichia coli and Staphylococcus saprophyticus Collected in the United States in 2022. Lead author: S.J. Ryan Arends, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.
Poster #2159
Evaluation of Isavuconazole Activity against Aspergillus fumigatus Causing Invasive Infections Worldwide Using the New CLSI Clinical Breakpoints
Evaluation of Isavuconazole Activity against Aspergillus fumigatus Causing Invasive Infections Worldwide Using the New CLSI Clinical Breakpoints. Lead author: Cecilia G. Carvalhaes, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.
Poster #P2113
Frequency, Antimicrobial Susceptibility, and Molecular Characterization of Carbapenem-Resistant Enterobacterales Stratified by United States Census Divisions: Results from the INFORM Program (2018–2022)
Frequency, Antimicrobial Susceptibility, and Molecular Characterization of Carbapenem-Resistant Enterobacterales Stratified by United States Census Divisions: Results from the INFORM Program (2018–2022). Lead author: Helio S. Sader, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.
Poster #2802
Comparative Activity of Oritavancin and Comparator Agents against Staphylococcus aureus and Streptococcus spp. Causing Skin and Soft Tissue Infections (SSTIs) in US Medical Centers between 2017–2019 and 2022
Comparative Activity of Oritavancin and Comparator Agents against Staphylococcus aureus and Streptococcus spp. Causing Skin and Soft Tissue Infections (SSTIs) in US Medical Centers between 2017–2019 and 2022. Lead author: Cecilia G. Carvalhaes, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.
Poster #1812
Activity of Aztreonam-Avibactam and Other β-Lactamase Inhibitor Combinations against Gram-negative Bacteria Isolated from Patients Hospitalized with Pneumonia in US Medical Centers (2020–2022)
Activity of Aztreonam-Avibactam and Other β-Lactamase Inhibitor Combinations against Gram-negative Bacteria Isolated from Patients Hospitalized with Pneumonia in US Medical Centers (2020–2022). Lead author: Helio S. Sader, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.
Poster #2598
Activity of Omadacycline and Comparators Against 876 Bacterial Clinical Isolates from Patients with Bone and Joint Infections in the United States and Europe (2015–2022)
Activity of Omadacycline and Comparators Against 876 Bacterial Clinical Isolates from Patients with Bone and Joint Infections in the United States and Europe (2015–2022). Lead author: Michael D. Huband, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.
Poster #1292
Cefiderocol Activity Against Multidrug-resistant and Molecularly Characterized Pseudomonas aeruginosa and Acinetobacter baumannii-calcoaceticus complex Clinical Isolates Causing Infection in United States Hospitals (2020–2022)
Cefiderocol Activity Against Multidrug-resistant and Molecularly Characterized Pseudomonas aeruginosa and Acinetobacter baumannii-calcoaceticus complex Clinical Isolates Causing Infection in United States Hospitals (2020–2022). Lead author: Rodrigo E. Mendes, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.
Poster #2174
Activity of Cefiderocol and Comparator Agents Against Molecularly Characterized Multidrug-resistant Enterobacterales Clinical Isolates From United States Hospitals (2020–2022)
Activity of Cefiderocol and Comparator Agents Against Molecularly Characterized Multidrug-resistant Enterobacterales Clinical Isolates From United States Hospitals (2020–2022). Lead author: Rodrigo E. Mendes, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.
Poster #2172
Development and validation of an internal bioinformatic pipeline for 16S rRNA amplicon sequencing
Development and validation of an internal bioinformatic pipeline for 16S rRNA amplicon sequencing. Lead author: Timothy B. Doyle, presented at ASM Microbe 2023, June 15-19, Houston, TX, USA
Impact of the COVID Pandemic in Susceptibility Patterns of Gram-Positive Organisms: A Report from the SENTRY Antimicrobial Surveillance Program
Impact of the COVID Pandemic in Susceptibility Patterns of Gram-Positive Organisms: A Report from the SENTRY Antimicrobial Surveillance Program. Lead Author: Cecilia G. Carvalhaes, presented at ASM Microbe, June 15-19, Houston, TX, USA
Antimicrobial Susceptibility Testing for β-lactam/β-lactamase Inhibitor Combination Agents Against Enterobacterales Isolates Harboring β-lactamase Resistance Genes from North and Latin America: Comparison of VITEK® 2 AES and Broth Microdilution Methods
Antimicrobial Susceptibility Testing for β-lactam/β-lactamase Inhibitor Combination Agents Against Enterobacterales Isolates Harboring β-lactamase Resistance Genes from North and Latin America: Comparison of VITEK® 2 AES and Broth Microdilution Methods. Lead Author: Cecilia G. Carvalhaes, presented at ASM Microbe 2023, June 15-19, Houston, TX, USA
In vitro activity of sulopenem and comparator agents against Enterobacterales and anaerobic clinical isolates collected during the SENTRY Antimicrobial Surveillance Program
In vitro activity of sulopenem and comparator agents against Enterobacterales and anaerobic clinical isolates collected during the SENTRY Antimicrobial Surveillance Program by JM Maher, MD Huband, CG Blankers, S Puttagunta, SI Aronin, and M Castanheira in J Antimicrob Chemother 78(4): 2023, dkad099.
Antimicrobial Activity of Gepotidacin Tested against Escherichia coli and Staphylococcus saprophyticus Isolates Causing Urinary Tract Infections in Medical Centers Worldwide (2019 to 2020)
Antimicrobial Activity of Gepotidacin Tested against Escherichia coli and Staphylococcus saprophyticus Isolates Causing Urinary Tract Infections in Medical Centers Worldwide (2019 to 2020) by SJR Arends, D Butler, N Scagarella-Oman, M Castanheira, and RE Mendes in Antimicrob Agents Chemother 67(4): 2023, e0152522.
Impact of the COVID Pandemic in Susceptibility Patterns of Gram- Negative Organisms: A Report from the SENTRY Antimicrobial Surveillance Program
Impact of the COVID Pandemic in Susceptibility Patterns of Gram-Negative Organisms: A Report from the SENTRY Antimicrobial Surveillance Program. Lead author: Mariana Castanheira. Presented at ECCMID 2023, April 15-18, Copenhagen.
Frequency of Occurrence and Antimicrobial Susceptibility of Bacteria Isolated from Patients Hospitalised with Pneumonia in Europe and United States: Results from the SENTRY Program (2019–2021)
Frequency of Occurrence and Antimicrobial Susceptibility of Bacteria Isolated from Patients Hospitalised with Pneumonia in Europe and United States: Results from the SENTRY Program (2019–2021). Lead author: Helio Sader. ECCMID 2023, April 15-18, Copenhagen.
In Vitro Activity of SPR206 and Comparator Compounds against Enterobacterales Isolates Responsible for Infections in Hospitals in Europe and Adjacent Regions
In Vitro Activity of SPR206 and Comparator Compounds against Enterobacterales Isolates Responsible for Infections in Hospitals in Europe and Adjacent Regions. Lead Author: Rodrigo Mendes, ECCMID 2023, April 15-18, Copenhagen.
